ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Is a Good Night's Sleep at the Top of Your Wishlist?

Ashwagandha Helps Hormones - Aids Arthritis

Why You Should Be Eating More Porcini Mushrooms

A Breathalyzer for Disease?

How Bacopa Can Help Improve Your Cognitive Function

Black Tea Is Great for Your Gut

Magnesium Reduces Diabetes and Helps Keep You Young

Lavender Aromatherapy Can Ease Pre-Op Anxiety

Mint: Learn More About This Refreshing and Invigorating Herb

Give Your Health a Much-Needed Boost With Geranium

 
Print Page
Email Article

First human tests under way of HIV vaccine pioneered at UNC

  [ 20 votes ]   [ Discuss This Article ]
www.ProHealth.com • August 7, 2003


CHAPEL HILL -- The world's first human test of a vaccine against the prevalent subtype of HIV in sub-Saharan African and Asia, where millions have the virus that causes AIDS, is now under way. The clinical trial uses novel technology pioneered by scientists at the University of North Carolina at Chapel Hill School of Medicine and the U. S. Army Medical Research Institute of Infectious Diseases.

The phase I trial began July 17 at Johns Hopkins University. An adult male, at low risk for HIV infection, was the first of 48 volunteers in the United States to be vaccinated.

Other U.S. sites include Columbia University, Vanderbilt University and the University of Rochester. Sites in South Africa are at the University of Witwatersrand, the Chris Hani Baragwanath Hospital in Soweto and the Medical Research Council in Durban. The two-year trial will involve 48 non-HIV-infected participants in each country at four different dose levels, using a double-blind, placebo-controlled design. The primary endpoint is safety, that the vaccine does not produce significant side effects. Researchers also will look at the vaccine's ability to induce an immune response.

The vaccine is built around a disabled, safe version of Venezuelan equine encephalitis virus, or VEE. In the wild, this microbe infects horses and is sometimes carried to humans via mosquitoes.

Dr. Robert E. Johnston, professor of microbiology and immunology and director of the newly established Carolina Vaccine Institute, together with department colleague and research professor Dr. Nancy Davis studied VEE for more than 12 years, developing candidate vaccines against the virus. Their work led them to believe the virus could be modified for use as a safe vaccine vector, or delivery system for the vaccine.

Subsequent primate tests showed the technology held promise. Now, with approval from the U.S. Food and Drug Administration and the South African Medicines Control Council, a prototype HIV vaccine based on VEE technology has moved on to a human trial.

Joining Johnston and Davis in designing this "first-generation" HIV vaccine were Dr. Ronald Swanstrom, professor of biochemistry and biophysics and director of the UNC Center for AIDS Research; Dr. Jeffrey Frelinger, professor and chair of microbiology and immunology at UNC; and Drs. David Montefiore of Duke University and Phil Johnson of the Children's Hospital Research Foundation in Columbus, Ohio. Collaborating scientists in South Africa, Drs. Carolyn Williamson, Lynn Morris and Salim Karim, also were key members of this team effort.

AlphaVax, a Durham-based biotechnology spinoff of UNC, holds the commercial license for the VEE technology from the university and contributed to the design and manufactured the trial vaccine.

"It's very rare that a basic scientist gets to see something go from a concept to an actual biological product that can be tried in human beings," Johnston said.

"The VEE vector we helped develop is a means of expressing genes - in this case we're expressing a gene in vivo - inside the person vaccinated. And those gene products then immunize the person against the disease."

The vaccine contains a copy of only a small section of genetic material from HIV and does not include genetic elements needed to reconstitute live HIV, thus precluding the possibility of causing HIV infection. The vaccine material is also designed so that its VEE components cannot generate VEE virus or cause VEE infection.

The vaccine targets cells in lymph nodes, the critical tissue of the immune system. The vector will produce the immunizing protein by expressing "gag," a major protein in the HIV particle. The protein then induces the body to respond immunologically to it.

More advanced versions of the vaccine will include expression of the HIV envelope and polymerase genes.

"We hope to refine this vaccine to the point that if an individual is subsequently exposed to HIV, they will be protected from disease," Johnston said.

"This is a good first start from the standpoint of determining if the vector will work well. We can measure both cell mediated and humoral (antibody) immunity to gag. We'll be able to see if none or one or both arms of the immune response are activated during the vaccination."

The research collaboration of Johnson, Davis, Swanstrom, Montefiore and Johnson is working on subsequent generations of the vaccine. "We want to see if we can do better both from the delivery side and the gene side," Johnston said.

"I think I can speak for everybody on this team that we are extremely gratified to have this clinical trial opportunity. We're very hopeful. This is a major milestone."



Support for the early development of the vaccine came from the U. S. Army Research and Development Command, the National Institute of Allergy and Infectious Diseases (NIAID) and the International AIDS Vaccine Initiative. The trial is being conducted by the HIV Vaccine Trials Network, which is funded and supported by NIAID, a component of the National Institutes of Health.



Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Optimized Curcumin Longvida® Ultra EPA  - Fish Oil


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Break Free From Fibromyalgia Break Free From Fibromyalgia
Safely Burn Away Body Fat Safely Burn Away Body Fat
Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value
Carry a Massage Therapist in Your Pocket Carry a Massage Therapist in Your Pocket
The Cellular Enzyme That Promotes Longevity And Reduces Fat Storage The Cellular Enzyme That Promotes Longevity And Reduces Fat Storage

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map